Is TherapeuticsMD, Inc. overvalued or undervalued?

As of 12 November 2024, the valuation grade for TherapeuticsMD, Inc. has moved from does not qualify to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 0.54 and an EV to Sales ratio of 5.29, which suggests that the market is pricing the company at a premium despite its poor performance. Additionally, the EV to EBITDA ratio stands at -3.66, reflecting significant operational challenges.
When compared to peers, TherapeuticsMD has a P/E ratio of -12.50, while Checkpoint Therapeutics, Inc. has a P/E of -6.58 and Journey Medical Corp. has a P/E of -18.70, highlighting that TherapeuticsMD is underperforming relative to its industry. The company's recent stock performance has been troubling, with a 1-year return of -34.94% compared to the S&P 500's 17.14%, reinforcing the notion that it is currently overvalued.